United Kingdom

People: Constellation Pharmaceuticals Inc (CNST.OQ)

CNST.OQ on NASDAQ Stock Exchange Global Select Market

23 Jul 2019
Change (% chg)

$0.05 (+0.51%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Raythatha, Jigar 

Mr. Jigar Raythatha severs as President and Chief Executive Officer, Director of the company since March 2017. Mr. Raythatha previously served as chief business officer of Jounce Therapeutics, Inc., a biotechnology company, from December 2012 to February 2017, where he helped build the company from its inception to a publicly traded research and development organization. Previously, he served as our head of corporate development from March 2009 to February 2013, where he led business development, strategy and program and alliance management functions. Prior to serving as our head of corporate development, Mr. Raythatha joined Red Abbey Venture Partners, LLC in 2005 and served as a Kauffman fellow from 2005 to 2007, principal from 2007 to 2009 and venture partner in 2009. Prior to Red Abbey Venture Partners, Mr. Raythatha worked at Biogen Inc. from 1999 to 2003 in a variety of business development, commercial, and program management roles. He earned an M.B.A. from Columbia University and a B.A. in biochemistry and economics from Rutgers University. We believe that Mr. Raythatha’s extensive leadership experience in the life sciences industry and his extensive knowledge of our company based on his prior role as our head of corporate development and in his current role as our chief executive officer qualify him to serve as a member of our board of directors.

Basic Compensation

Total Annual Compensation, USD 464,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 2,544,940
Fiscal Year Total, USD 3,008,940

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --